Wachablösung bei der Feuerwehr Knittlingen - Region - Pforzheimer-Zeitung pz-news.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pz-news.de Daily Mail and Mail on Sunday newspapers.
Kungl. Vetenskapsakademien: New knowledge about a cancer pharmaceutical led to the Sjöberg Prize
MALMÖ, Sweden, Feb. 15, 2021 /PRNewswire/
Benjamin L. Ebert, USA, receives this year s Sjöberg Prize, worth one million US dollars, for his research into how lenalidomide works as a treatment for blood cancer. His discovery of the mechanism that promotes protein breakdown in cancer cells may be vitally important to the future development of new pharmaceuticals.
The story of this pharmaceutical begins with a tragedy as, in the 1950s and 1960s, pregnant women with severe morning sickness were sometimes given thalidomide. This caused a range of birth defects and the medication was removed from the market.
Benjamin L. Ebert, USA, receives this year's Sjöberg Prize, worth one million US dollars, for his research into how lenalidomide works as a treatment for blood cancer.
Date Time
Dana-Farber Medical Oncology Chair receives Sjöberg Prize for cancer research
Benjamin Ebert, MD, PhD, Chair of Medical Oncology at Dana-Farber Cancer Institute, George P. Canellos, MD, and Jean S. Canellos Professor of Medicine at Harvard Medical School, and Institute Member of Broad Institute of Harvard and MIT, has been awarded the Sjöberg Prize, an annual international prize in cancer research. The prize was awarded for Dr. Ebert’s discovery of the mode of action of lenalidomide in the treatment of hematological disorders.
This is the fifth time that the Sjöberg Prize will be awarded. The Royal Swedish Academy of Sciences selects the laureates and the Sjöberg Foundation provides the financing. The prize amounts to one million dollars, of which $100,000 is the prize sum and $900,000 is funding for future research.
CAR T cells are a breakthrough class of effective but often toxic cancer therapies
To prevent overactivation, switchable CAR T cells were engineered that can be turned on and off with an approved, widely used cancer drug
BOSTON - Scientists at Dana-Farber Cancer Institute and Mass General Cancer Center have created molecular ON-OFF switches to regulate the activity of CAR T cells, a potent form of cell-based immunotherapy that has had dramatic success in treating some advanced cancers, but which pose a significant risk of toxic side effects.
CAR T cells are immune cells genetically modified to recognize and attack tumors cells. Once given, these living drugs proliferate and kill tumor cells over weeks to months, in some cases causing life-threatening inflammatory reactions that are difficult to control. In this way, CAR T cells are unlike more established forms of cancer therapy - chemotherapy or radiotherapy for instance - whose dose can be precisely tuned up or down over tim